Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1274001 | 0.88 | POLB (0.41) | SMN1; SMN2ALDH1A1TDP1LMNAMEN1 | |
| SCHEMBL12621316 | 0.88 | HPGD (0.47) | BTN3A1SMN1; SMN2CYP1A2EPHX2ALDH1A1 | |
| SCHEMBL13875622 | 0.88 | BTN3A1 (0.44) | BTN3A1SMN1; SMN2ALDH1A1TDP1LMNA | |
| SCHEMBL14466574 | 0.88 | BTN3A1 (0.57) | BTN3A1SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL21158533 | 0.88 | BTN3A1 (0.57) | BTN3A1SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL23992573 | 0.88 | BTN3A1 (0.57) | BTN3A1SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL807682 | 0.88 | BTN3A1 (0.57) | BTN3A1SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL21023979 | 0.87 | BTN3A1 (0.41) | BTN3A1CYP1A2ALDH1A1LMNAMEN1 | |
| SCHEMBL12621322 | 0.87 | BTN3A1 (0.41) | BTN3A1CYP1A2ALDH1A1LMNAMEN1 | |
| SCHEMBL12900829 | 0.86 | MEN1 (0.46) | BTN3A1SMN1; SMN2ABCB11CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47589-E1 | Phosphoramidate compounds and methods of use | NuCana plc (GB) | 2019-09-03 | — | — | US | disclosed |
| EP-2120565-B1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK SHARP & DOHME (US) | 2012-11-28 | — | — | EP | disclosed |
| US-8148349-B2 | Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-04-03 | — | — | US | disclosed |
| US-8148349-B2 | Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-04-03 | — | — | US | disclosed |
| US-8148349-B2 | Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-04-03 | — | — | US | disclosed |
| US-7951787-B2 | Phosphoramidate compounds and methods of use | CARDIFF PROTIDES LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-7951787-B2 | Phosphoramidate compounds and methods of use | CARDIFF PROTIDES LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-7879815-B2 | inhibitors of viral polymerases such as 5'-O-[[4-chloro-5-methyl-2-(1-methylethyl)phenoxy][[(1S)-2-ethoxy-1-methyl-2-oxoethyl]amino]phosphinyl]-2'-C-methylcytidine, used for the treatment of hepatitis C virus infection in mammals | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879815-B2 | inhibitors of viral polymerases such as 5'-O-[[4-chloro-5-methyl-2-(1-methylethyl)phenoxy][[(1S)-2-ethoxy-1-methyl-2-oxoethyl]amino]phosphinyl]-2'-C-methylcytidine, used for the treatment of hepatitis C virus infection in mammals | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100234316-A1 | Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection | MSD ITALIA S.R.L. (IT) | 2010-09-16 | — | — | US | disclosed |
| US-20100234316-A1 | Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection | MSD ITALIA S.R.L. (IT) | 2010-09-16 | — | — | US | disclosed |
| US-20100022468-A1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK SHARP & DOHME LLC | 2010-01-28 | — | — | US | disclosed |
| US-20100022468-A1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK SHARP & DOHME LLC | 2010-01-28 | — | — | US | disclosed |
| US-20100022468-A1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK SHARP & DOHME LLC | 2010-01-28 | — | — | US | disclosed |
| EP-2120565-A1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-1987050-A2 | NUCLEOSIDE ARYL PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | Merck & Co., Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008079206-A1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK & CO., INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2007095269-A2 | NUCLEOSIDE ARYL PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK & CO., INC. (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234316-A1 | Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection | NSUN2, NSUN3, RNGTT | BTN3A1 3819/4885SMN1; SMN2 2938/4885ABCB11 1127/4885 |
| US-20100022468-A1 | NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | RNGTT, NSUN2, RNASE1 | BTN3A1 3938/4885SMN1; SMN2 3096/4885ABCB11 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.